Cyclo Therapeutics Inc (CYTH)
0.7216
-0.03
(-3.53%)
USD |
NASDAQ |
Nov 01, 16:00
0.7228
0.00 (0.00%)
After-Hours: 20:00
Cyclo Therapeutics Net Income (Quarterly): -5.981M for June 30, 2024
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | -5.981M |
| March 31, 2024 | -4.343M |
| December 31, 2023 | -5.642M |
| September 30, 2023 | -4.771M |
| June 30, 2023 | -4.636M |
| March 31, 2023 | -5.007M |
| December 31, 2022 | -4.980M |
| September 30, 2022 | -4.247M |
| June 30, 2022 | -3.452M |
| March 31, 2022 | -2.772M |
| December 31, 2021 | -2.792M |
| September 30, 2021 | -3.860M |
| June 30, 2021 | -3.597M |
| March 31, 2021 | -4.037M |
| December 31, 2020 | -2.680M |
| September 30, 2020 | -1.436M |
| June 30, 2020 | -2.192M |
| March 31, 2020 | -2.634M |
| December 31, 2019 | -2.635M |
| September 30, 2019 | -1.625M |
| June 30, 2019 | -1.368M |
| March 31, 2019 | -1.904M |
| December 31, 2018 | -1.366M |
| September 30, 2018 | -0.7873M |
| June 30, 2018 | -1.289M |
| Date | Value |
|---|---|
| March 31, 2018 | -0.8129M |
| December 31, 2017 | -1.384M |
| September 30, 2017 | -0.6337M |
| June 30, 2017 | -0.8278M |
| March 31, 2017 | -0.9875M |
| December 31, 2016 | -0.832M |
| September 30, 2016 | -1.615M |
| June 30, 2016 | -1.071M |
| March 31, 2016 | -0.7058M |
| December 31, 2015 | -1.055M |
| September 30, 2015 | -0.7476M |
| June 30, 2015 | -0.3602M |
| March 31, 2015 | -0.3883M |
| December 31, 2014 | -0.3173M |
| September 30, 2014 | -0.2209M |
| June 30, 2014 | -0.1514M |
| March 31, 2014 | 0.0969M |
| December 31, 2013 | -0.0844M |
| September 30, 2013 | -0.0945M |
| June 30, 2013 | 0.2637M |
| March 31, 2013 | 0.1201M |
| December 31, 2012 | 0.1306M |
| September 30, 2012 | -0.0457M |
| June 30, 2012 | -0.0564M |
| March 31, 2012 | 0.0458M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
-5.981M
Minimum
Jun 2024
-1.436M
Maximum
Sep 2020
-3.774M
Average
-3.860M
Median
Sep 2021
Net Income (Quarterly) Benchmarks
| Stryker Corp | 834.00M |
| Biogen Inc | 388.50M |
| Pfizer Inc | 4.465B |
| Pacira BioSciences Inc | 18.89M |
| Moderna Inc | -1.279B |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 0.1231M |
| Total Expenses (Quarterly) | 5.759M |
| EPS Diluted (Quarterly) | -0.21 |
| Enterprise Value | 22.30M |
| Gross Profit Margin (Quarterly) | 89.13% |
| Profit Margin (Quarterly) | -4.86K% |
| Earnings Yield | -122.0% |
| Normalized Earnings Yield | -122.07 |